Roanna Ruiz
Stock Analyst at Leerink Partners
(0.60)
# 3,845
Out of 4,761 analysts
59
Total ratings
25%
Success rate
-21.28%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $9.57 | +108.99% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $11.24 | +140.21% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.01 | +331.89% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.06 | +176.68% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $361.10 | -8.61% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $50.26 | +15.40% | 1 | Aug 15, 2023 | |
| CORT Corcept Therapeutics | Initiates: Market Perform | $25 | $63.54 | -60.65% | 1 | Apr 11, 2023 | |
| ENTA Enanta Pharmaceuticals | Reiterates: Market Perform | $49 | $8.03 | +510.21% | 10 | Feb 9, 2023 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $5 | $3.75 | +33.33% | 4 | Jan 27, 2023 | |
| SCPH scPharmaceuticals | Maintains: Outperform | $12 → $13 | $3.25 | +300.00% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.09 | +94.17% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $18.57 | +2.32% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $78.23 | +53.39% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $18.63 | +168.38% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $2 | $0.59 | +239.50% | 6 | Oct 19, 2022 |
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $9.57
Upside: +108.99%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $11.24
Upside: +140.21%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.01
Upside: +331.89%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.06
Upside: +176.68%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $361.10
Upside: -8.61%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $50.26
Upside: +15.40%
Corcept Therapeutics
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $63.54
Upside: -60.65%
Enanta Pharmaceuticals
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $8.03
Upside: +510.21%
Xeris Biopharma Holdings
Jan 27, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $3.75
Upside: +33.33%
scPharmaceuticals
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $3.25
Upside: +300.00%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.09
Upside: +94.17%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $18.57
Upside: +2.32%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $78.23
Upside: +53.39%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $18.63
Upside: +168.38%
Oct 19, 2022
Maintains: Market Perform
Price Target: $3 → $2
Current: $0.59
Upside: +239.50%